Fluorescein kinetics in interstitial fluid harvested from diabetic skin during fluorescein angiography: implications for glucose monitoring.

Abstract:

BACKGROUND:Glucose monitoring based on sampling skin interstitial fluid (ISF) is being developed as an alternative to fingerstick blood glucose monitoring. Time delays between rapidly changing levels of glucose in blood and interstitial fluid have been reported in the literature to be between 5 and 20 minutes. This study investigated the time delay between the injection of a small molecular weight fluorescent tracer into the circulation and interstitial fluid. METHODS:Diabetic subjects undergoing fluorescein angiography were studied. Skin ISF was sampled using a proprietary microporation and harvesting process. ISF was drawn through micropores created in the stratum corneum. After intravenous injection of sodium fluorescein, samples of ISF were drawn from 2 sites for 30 seconds over a period of 20 minutes. Fluorescence levels in ISF were measured with a fluorometer and used to create ISF fluorescein concentration versus time profiles. RESULTS:The ISF fluorescein versus time profiles were characterized by a rapid rise followed by a slow decay. The time to peak of the ISF fluorescein concentration ranged from 2-4 minutes for the patients studied. CONCLUSIONS:Intravenous injection of a bolus of low molecular weight fluorescent tracer was used to estimate the time delay between changing glucose levels in blood and ISF. The results indicate that the ISF sampling technology utilized here is capable of tracking rapidly rising levels of blood glucose.

journal_name

Diabetes Technol Ther

authors

Smith A,Yang D,Delcher H,Eppstein J,Williams D,Wilkes S

doi

10.1089/152091599317530

keywords:

subject

Has Abstract

pub_date

1999-04-01 00:00:00

pages

21-7

issue

1

eissn

1520-9156

issn

1557-8593

journal_volume

1

pub_type

杂志文章
  • Evaluation of hemoglobin A1c criteria to assess preoperative diabetes risk in cardiac surgery patients.

    abstract:OBJECTIVE:Hemoglobin A1c (A1C) has recently been recommended for diagnosing diabetes mellitus and diabetes risk (prediabetes). Its performance compared with fasting plasma glucose (FPG) and 2-h post-glucose load (2HPG) is not well delineated. We compared the performance of A1C with that of FPG and 2HPG in preoperative ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0074

    authors: Gianchandani RY,Saberi S,Zrull CA,Patil PV,Jha L,Kling-Colson SC,Gandia KG,DuBois EC,Plunkett CD,Bodnar TW,Pop-Busui R

    更新日期:2011-12-01 00:00:00

  • The effect of capsule composition in the reversal of hyperglycemia in diabetic mice transplanted with microencapsulated allogeneic islets.

    abstract::The transplantation of microencapsulated islets may allow reversal of hyperglycemia in the absence of immunosuppression. Poly-L-lysine (PLL) on capsules may potentiate the fibrotic reaction against implanted capsules. The aims of this study were to investigate how the biocompatibility of such capsules affects their fu...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091503322250677

    authors: King A,Lau J,Nordin A,Sandler S,Andersson A

    更新日期:2003-01-01 00:00:00

  • Venous, Arterialized-Venous, or Capillary Glucose Reference Measurements for the Accuracy Assessment of a Continuous Glucose Monitoring System.

    abstract:BACKGROUND:Different reference methods are used for the accuracy assessment of continuous glucose monitoring (CGM) systems. The effect of using venous, arterialized-venous, or capillary reference measurements on CGM accuracy is unclear. METHODS:We evaluated 21 individuals with type 1 diabetes using a capillary calibra...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,随机对照试验

    doi:10.1089/dia.2017.0189

    authors: Kropff J,van Steen SC,deGraaff P,Chan MW,van Amstel RBE,DeVries JH

    更新日期:2017-11-01 00:00:00

  • Assessment of a new insulin preparation for implanted pumps used in the treatment of type 1 diabetes.

    abstract:BACKGROUND:Implanted insulin pumps using the peritoneal route provide long-term improvement of glucose control compared with subcutaneous insulin therapy in type 1 diabetes (T1D) patients. The stability of insulin preparation is critical for a safe use in implanted pumps. Insuman implantable(®) (400 IU/mL) (Sanofi-Aven...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究,随机对照试验

    doi:10.1089/dia.2013.0369

    authors: Schaepelynck P,Riveline JP,Renard E,Hanaire H,Guerci B,Baillot-Rudoni S,Sola-Gazagnes A,Catargi B,Fontaine P,Millot L,Martin JF,Tachouaft H,Jeandidier N,EVADIAC Group.

    更新日期:2014-09-01 00:00:00

  • Area of the diabetic ulcers estimated applying a foot scanner-based home telecare system and three reference methods.

    abstract:BACKGROUND:Diabetic foot ulcer area is a basic parameter used for monitoring the wound healing and effectiveness of the treatment applied. TeleDiaFoS (developed earlier in collaboration with the Department and Clinic of Gastroenterology and Metabolic Diseases, Medical University of Warsaw, Warsaw, Poland) is one of jus...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0082

    authors: Ladyzynski P,Foltynski P,Molik M,Tarwacka J,Migalska-Musial K,Mlynarczuk M,Wojcicki JM,Krzymien J,Karnafel W

    更新日期:2011-11-01 00:00:00

  • The impact of initiating biphasic human insulin 30 therapy in type 2 diabetes patients after failure of oral antidiabetes drugs.

    abstract:BACKGROUND:The present study evaluated the efficacy of biphasic human insulin 30 (BHI 30) in type 2 diabetes patients who had failed in therapy with two or more oral antidiabetes drugs (OADs). METHODS:This open-label, nonrandomized, 4-month, multicenter, clinical observational study was conducted in Shanghai, China. A...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2011.0168

    authors: Gu Y,Hou X,Zhang L,Pan J,Cai Q,Bao Y,Jia W

    更新日期:2012-03-01 00:00:00

  • Safety and Performance of the Omnipod Hybrid Closed-Loop System in Adults, Adolescents, and Children with Type 1 Diabetes Over 5 Days Under Free-Living Conditions.

    abstract:: Background: The objective of this study was to assess the safety and performance of the Omnipod® personalized model predictive control (MPC) algorithm in adults, adolescents, and children aged ≥6 years with type 1 diabetes (T1D) under free-living conditions using an invest...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1089/dia.2019.0286

    authors: Sherr JL,Buckingham BA,Forlenza GP,Galderisi A,Ekhlaspour L,Wadwa RP,Carria L,Hsu L,Berget C,Peyser TA,Lee JB,O'Connor J,Dumais B,Huyett LM,Layne JE,Ly TT

    更新日期:2020-03-01 00:00:00

  • A pilot study of the SPRINT protocol for tight glycemic control in critically Ill patients.

    abstract:BACKGROUND:Stress-induced hyperglycemia is prevalent in critical care, even in patients with no history of diabetes. Increased counter-regulatory hormone response increases gluconeogenesis and effective insulin resistance, which can be exacerbated by drug therapy. Control of blood glucose levels to the 4.0-6.1 mmol/L r...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2006.8.449

    authors: Lonergan T,Compte AL,Willacy M,Chase JG,Shaw GM,Hann CE,Lotz T,Lin J,Wong XW

    更新日期:2006-08-01 00:00:00

  • Waist circumference identifies primary school children with metabolic syndrome abnormalities.

    abstract:OBJECTIVE:This study was designed to assess whether waist circumference can predict metabolic syndrome abnormalities in primary schoolchildren. RESEARCH DESIGN AND METHODS:Of 5,103 children (2,526 males) 4-13 years old who underwent anthropometric measurements, 530 had more extensive testing. Body mass index (BMI), wa...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2006.0017

    authors: Hirschler V,Maccallini G,Calcagno M,Aranda C,Jadzinsky M

    更新日期:2007-04-01 00:00:00

  • Alternative delivery of insulin via eye drops.

    abstract:BACKGROUND:Various insulin delivery systems have been considered for systemic absorption other than injections. Although the ocular route has been suggested, its use is limited by the amount of insulin absorbed systemically via eyes. In order to improve the absorption rate of insulin into systemic circulations, the eff...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2005.7.695

    authors: Xuan B,McClellan DA,Moore R,Chiou GC

    更新日期:2005-10-01 00:00:00

  • Integrating Continuous Glucose Monitor Data Directly into the Electronic Health Record: Proof of Concept.

    abstract:: Background: Continuous glucose monitoring (CGM) systems are widely and increasingly used in diabetes self-management and in the context of clinic visits. However, access to CGM data during visits can be challenging. Clinic inefficiencies can restrict the time available for...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0377

    authors: Espinoza J,Shah P,Raymond J

    更新日期:2020-08-01 00:00:00

  • Increased Time in Range and Fewer Missed Bolus Injections After Introduction of a Smart Connected Insulin Pen.

    abstract:: Background: This observational study investigated whether the connected NovoPen® 6 could influence insulin regimen management and glycemic control in people with type 1 diabetes (T1D) using a basal-bolus insulin regimen and continuous glucose monitoring in a real-world set...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0411

    authors: Adolfsson P,Hartvig NV,Kaas A,Møller JB,Hellman J

    更新日期:2020-10-01 00:00:00

  • Design and Clinical Evaluation of the Interoperable Artificial Pancreas System (iAPS) Smartphone App: Interoperable Components with Modular Design for Progressive Artificial Pancreas Research and Development.

    abstract:BACKGROUND:There is an unmet need for a modular artificial pancreas (AP) system for clinical trials within the existing regulatory framework to further AP research projects from both academia and industry. We designed, developed, and tested the interoperable artificial pancreas system (iAPS) smartphone app that can int...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2018.0278

    authors: Deshpande S,Pinsker JE,Zavitsanou S,Shi D,Tompot R,Church MM,Andre C,Doyle FJ 3rd,Dassau E

    更新日期:2019-01-01 00:00:00

  • Development and Validation of the Continuous Subcutaneous Insulin Infusion-Related Quality-of-Life (CSII-QOL) Scale.

    abstract:: Background: Continuous subcutaneous insulin infusion (CSII) is associated with improved glycemic control, a reduced incidence of hypoglycemia, and improved quality of life (QOL). To date, however, there has been no QOL scale specific to CSII. The objective of this study wa...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0216

    authors: Sakane N,Murata T,Tone A,Kato K,Kimura M,Kawashima S,Sawaki H,Hirota Y,Okada A,Kuroda A,Matsuhisa M,Watanabe T,Suganuma A,Nirengi S,Toyoda M

    更新日期:2020-03-01 00:00:00

  • Self-Monitoring of Blood Glucose (SMBG) in insulin- and non-insulin-using adults with diabetes: consensus recommendations for improving SMBG accuracy, utilization, and research.

    abstract::Current clinical guidelines for diabetes care encourage self-monitoring of blood glucose (SMBG) to improve glycemic control. Specific protocols remain variable, however, particularly among non-insulin-using patients. This is due in part to efficacy studies that neglect to consider (1) the performance of monitoring equ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2008.0104

    authors: Hirsch IB,Bode BW,Childs BP,Close KL,Fisher WA,Gavin JR,Ginsberg BH,Raine CH,Verderese CA

    更新日期:2008-12-01 00:00:00

  • A highly sensitive immunoassay resistant to autoantibody interference for detection of the diabetes-associated autoantigen glutamic acid decarboxylase 65 in blood and other biological samples.

    abstract:BACKGROUND:Glutamic acid decarboxylase-65 (GAD65) is a major autoantigen in autoimmune diabetes and is discharged from injured islet beta cells. GAD65 may also be released by transplanted islets undergoing immunological rejection. To test hypotheses regarding the utility of GAD65 as a biomarker for transplant rejection...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2006.8.207

    authors: Waldrop MA,Suckow AT,Hall TR,Hampe CS,Marcovina SM,Chessler SD

    更新日期:2006-04-01 00:00:00

  • Lipoprotein-associated phospholipase A₂ activity predicts progression of subclinical coronary atherosclerosis.

    abstract:BACKGROUND:Lipoprotein-associated phospholipase A₂ (Lp-PLA₂) is a lipoprotein-associated enzyme that cleaves oxidized phosphatidylcholines, generating pro-atherosclerotic lysophosphatidylcholine and oxidized free fatty acids. Lp-PLA₂ is independently associated with cardiovascular disease (CVD) in a variety of populati...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0175

    authors: Kinney GL,Snell-Bergeon JK,Maahs DM,Eckel RH,Ehrlich J,Rewers M,Hokanson JE

    更新日期:2011-03-01 00:00:00

  • Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study.

    abstract:BACKGROUND:Long-term treatment is necessary to slow the progression of type 2 diabetes (T2D). Here, we examined the safety and efficacy of 6 years of treatment with exenatide once weekly (QW) among patients with T2D in the DURATION-1 trial. METHODS:The study enrolled patients aged ≥16 years with T2D treated primarily ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 临床试验,杂志文章

    doi:10.1089/dia.2016.0107

    authors: Henry RR,Klein EJ,Han J,Iqbal N

    更新日期:2016-11-01 00:00:00

  • Usage of the www.2aida.org AIDA diabetes software Website: a pilot study.

    abstract::AIDA is a diabetes-computing program freely available from www.2aida.org on the Web. The software is intended to serve as an educational support tool, and can be used by anyone who has an interest in diabetes, whether they be patients, relatives, health-care professionals, or students. In previous "Diabetes Informatio...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091503763816490

    authors: Lehmann ED

    更新日期:2003-01-01 00:00:00

  • High glycemic variability assessed by continuous glucose monitoring after surgical treatment of obesity by gastric bypass.

    abstract:BACKGROUND:Obesity surgery elicits complex changes in glucose metabolism that are difficult to observe with discontinuous glucose measurements. We aimed to evaluate glucose variability after gastric bypass by continuous glucose monitoring (CGM) in a real-life setting. METHODS:CGM was performed for 4.2 ± 1.3 days in th...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2010.0203

    authors: Hanaire H,Bertrand M,Guerci B,Anduze Y,Guillaume E,Ritz P

    更新日期:2011-06-01 00:00:00

  • Continuous glucose monitoring and diabetes health outcomes: a critical appraisal.

    abstract::This paper presents a critical review of continuous glucose monitoring studies that address accuracy, utility in assessing glucose variability, detection of hypoglycemia for improved metabolic control or reduced glucose variability, impact on quality of life, reduced fear of hypoglycemia, and applicability in helping ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2007.0261

    authors: Reach G

    更新日期:2008-04-01 00:00:00

  • The emergence of biosimilar insulin preparations--a cause for concern?

    abstract::Several biopharmaceuticals, including insulin and insulin analogs, are, or shortly will be, off-patent, thereby providing an opportunity for companies to attempt to manufacture "copies" commonly referred to as biosimilars and also known as follow-on biologics. Reassurance that such copy biologics are equally safe and ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2012.0105

    authors: Owens DR,Landgraf W,Schmidt A,Bretzel RG,Kuhlmann MK

    更新日期:2012-11-01 00:00:00

  • Description and preliminary evaluation of a Multiagent Intelligent Dosing System (MAIDS) to manage combination insulin-oral agent therapy in type 2 diabetes.

    abstract:BACKGROUND:Computer decision support systems are potentially effective methods for adjusting insulin, but current models do not take into account simultaneous changes of more than one agent. We describe the development of the Multiagent Intelligent Dosing System (MAIDS, Dimensional Dosing Systems, Wexford, PA) for pred...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2005.7.937

    authors: Cook CB,McMichael JP,Dunbar VG,Lieberman R

    更新日期:2005-12-01 00:00:00

  • Human factors research applied: the development of a personal touch screen insulin pump and users' perceptions of actual use.

    abstract:BACKGROUND:A brief history of the field of human factors research is covered, along with how this discipline is leveraged within medical device companies, to eliminate design flaws in products, in order to make them safe and effective for human use. The way in which human factors research was used to develop the t:slim...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,多中心研究

    doi:10.1089/dia.2013.0098

    authors: Schaeffer NE

    更新日期:2013-10-01 00:00:00

  • Personal glycation factors and calculated HbA1c for diabetes management: Real-world data from the DPV registry.

    abstract::Background Glycated hemoglobin A1c (HbA1c) is a key biomarker in the glycemic management of individuals with diabetes but the relationship with glucose levels can be variable. A recent kinetic model has described a calculated HbA1c (cHbA1c) that is individual-specific. Our aim was to validate the routine clinical use ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2020.0553

    authors: Xu Y,Grimsmann JM,Karges B,Hofer SE,Danne T,Holl RW,Ajjan RA,Dunn TD

    更新日期:2021-01-04 00:00:00

  • Clinical studies on chromium picolinate supplementation in diabetes mellitus--a review.

    abstract::Chromium (Cr) picolinate (CrPic) is a widely used nutritional supplement for optimal insulin function. A relationship among Cr status, diabetes, and associated pathologies has been established. Virtually all trials using CrPic supplementation for subjects with diabetes have demonstrated beneficial effects. Thirteen of...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章,评审

    doi:10.1089/dia.2006.8.677

    authors: Broadhurst CL,Domenico P

    更新日期:2006-12-01 00:00:00

  • Where Do We Stand with Closed-Loop Systems and Their Challenges?

    abstract::Treatments for type 1 diabetes have advanced significantly over recent years. There are now multiple hybrid closed-loop systems commercially available and additional systems are in development. Challenges remain, however. This review outlines the recent advances in closed-loop systems and outlines the remaining challe...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2019.0469

    authors: Jackson M,Castle JR

    更新日期:2020-07-01 00:00:00

  • Development of optimal kids insulin dosing system formulas for young children with type 1 diabetes mellitus.

    abstract:OBJECTIVE:This study was designed to develop predictive formulas for precise insulin dosing in young children with type 1 diabetes (T1DM). RESEARCH DESIGN AND METHODS:Consecutive 1-year data from a group of 14 young patients (eight girls, six boys) 3.9 ± 0.8 years old with diabetes duration of 2.0 ± 0.8 years, transit...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2011.0184

    authors: Alemzadeh R,Hoffmann RG,Dasgupta M,Parton E

    更新日期:2012-05-01 00:00:00

  • Inaccurate Glucose Sensor Values After Hydroxyurea Administration.

    abstract:: Objective: To assess the degree, duration, mean absolute relative difference (MARD), and error analysis of discrepant values per continuous glucose monitoring (CGM) systems after hydroxyurea (HU) administration. Research Design and Methods: ...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/dia.2020.0490

    authors: Tellez SE,Hornung LN,Courter JD,Abu-El-Haija M,Nathan JD,Lawson SA,Elder DA

    更新日期:2020-12-30 00:00:00

  • The effect of local subcutaneous delivery of vascular endothelial growth factor on the function of a chronically implanted amperometric glucose sensor.

    abstract::The foreign body capsule that forms around implanted devices such as glucose sensors is hypovascular and has limited permeability to glucose. Such a capsule may function better if well vascularized. We hypothesized that capsular vascularization achieved by local release of vascular endothelial growth factor (VEGF) wou...

    journal_title:Diabetes technology & therapeutics

    pub_type: 杂志文章

    doi:10.1089/152091504773731320

    authors: Ward WK,Wood MD,Casey HM,Quinn MJ,Federiuk IF

    更新日期:2004-04-01 00:00:00